A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Mexico
Latest Information Update: 04 Jun 2024
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
Most Recent Events
- 29 May 2024 Status changed from recruiting to completed.
- 31 Oct 2023 Planned primary completion date changed from 20 Sep 2023 to 3 May 2024.
- 10 Aug 2023 Planned End Date changed from 2 Feb 2024 to 3 May 2024.